Vigil Neuroscience, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Atlas Venture entities disposed of their shares in Vigil Neuroscience, Inc. as part of its merger with Sanofi, receiving $8.00 cash plus a $2.00 contingent value right per share.
Vigil Neuroscience, Inc. director Mary Thistle reports disposal of shares and options following the company's acquisition by Sanofi for $8.00 cash plus a $2.00 CVR per share.
Vigil Neuroscience's Chief Medical Officer, Petra Kaufmann, converted her stock options into cash and contingent value rights following the company's merger with Sanofi.
A Form 4 filing reveals Vigil Neuroscience Director Samantha L. Budd Haeberlein's equity disposition following the company's merger with Sanofi.
Vigil Neuroscience's CFO, Jennifer Lynn Ziolkowski, disposed of all her common stock and stock options following the company's acquisition by Sanofi on August 5, 2025.
Vigil Neuroscience, Inc. has been acquired by Sanofi, converting shares and options into cash and contingent value rights.
Vigil Neuroscience, Inc. has been acquired by Sanofi, with shareholders receiving $8.00 cash per share plus a contingent value right of $2.00.
Vigil Neuroscience CEO Ivana Magovcevic-Liebisch disposed of all her common stock and stock options as part of the company's acquisition by Sanofi, effective August 5, 2025.
Vigil Neuroscience, Inc. has been acquired by Sanofi, with shareholders receiving $8.00 cash plus a $2.00 contingent value right per share.
Vigil Neuroscience's Chief Science Officer, David L. F. Gray, disposed of stock options following the company's acquisition by Sanofi, converting them into cash and contingent value rights.
Cheryl R. Blanchard, a director at Vigil Neuroscience, disposed of shares and stock options due to the merger with Sanofi, receiving cash and contingent value rights.
A director of Vigil Neuroscience, Gerhard Koenig, disposed of common stock and stock options following the company's acquisition by Sanofi.
Vigil Neuroscience, Inc. Director Bruce Booth was granted 5,000 Restricted Stock Units (RSUs) as part of his compensation, with vesting scheduled for May 2026 or the next annual meeting.
Vigil Neuroscience, Inc. Director Stefan Vitorovic was granted 5,000 Restricted Stock Units (RSUs) on May 22, 2025, as part of the company's incentive plan.
Vigil Neuroscience, Inc. Director Suzanne Louise Bruhn was granted 5,000 Restricted Stock Units (RSUs) on May 22, 2025, as part of the company's 2021 Stock Option and Incentive Plan.
Vigil Neuroscience, Inc. Director Gerhard Koenig was granted 5,000 Restricted Stock Units, which will vest by May 2026 or the next annual meeting.
Vigil Neuroscience, Inc. Director Samantha L. Budd Haeberlein has been granted 5,000 Restricted Stock Units (RSUs) as part of the company's 2021 Stock Option and Incentive Plan, increasing her beneficial ownership to 17,000 shares.
Vigil Neuroscience, Inc. Director Cheryl R. Blanchard has been granted 5,000 Restricted Stock Units (RSUs) as part of her compensation, aligning her interests with shareholder value.
Vigil Neuroscience, Inc. Director Mary Thistle has acquired 5,000 Restricted Stock Units (RSUs) on May 22, 2025, as part of the company's 2021 Stock Option and Incentive Plan.
Petra Kaufmann, Chief Medical Officer of Vigil Neuroscience, Inc., was granted a stock option award for 144,000 shares on March 3, 2025.
Jennifer Lynn Ziolkowski, CFO of Vigil Neuroscience, reports the acquisition of a stock option award for 156,000 shares.
Suzanne Louise Bruhn, a director at Vigil Neuroscience, Inc., was granted a stock option award for 33,875 shares on March 3, 2025.
Ivana Magovcevic-Liebisch, President and CEO of Vigil Neuroscience, Inc., was granted a stock option award for 485,000 shares on March 3, 2025.
David L.F. Gray, Chief Science Officer of Vigil Neuroscience, Inc., reports the acquisition of stock options.
Director Bruce Booth of Vigil Neuroscience, Inc. was granted a stock option award for 48,393 shares in lieu of cash compensation, vesting quarterly starting March 31, 2025.
A Vigil Neuroscience director, Samantha L. Budd Haeberlein, purchased 12,000 shares of common stock at an average price of $1.71.
Vigil Neuroscience's CEO, Ivana Magovcevic-Liebisch, purchased 5,000 shares of common stock at an average price of $1.68 per share.
Vigil Neuroscience's CEO, Ivana Magovcevic-Liebisch, purchased 5,000 shares of common stock at $1.67 per share on December 18, 2024.
Vigil Neuroscience's President and CEO, Ivana Magovcevic-Liebisch, purchased 5,000 shares of common stock at an average price of $2.34 per share.
Director Stefan Vitorovic of Vigil Neuroscience, Inc. was granted a stock option award for 18,068 shares on June 5, 2024.